Drug intelligence / Profile preview

YDB102

Development stage: Preclinical
Lead developer: YD Global Life Science

Overview

YDB102 is an experimental oncology drug candidate currently in the preclinical stage of development by YD Global Life Science. The drug is designed to modulate multigene expression, a strategy aimed at addressing the complex genetic dysregulation characteristic of various cancers. As of the latest pipeline updates, YDB102 has achieved proof-of-concept (POC) in in-vivo animal models, marking its status as a preclinical "hit" candidate. While specific details regarding its chemical modality or precise molecular targets remain proprietary, the program focuses on the broad regulation of gene expression networks involved in oncogenesis.

Beyond the preview

Go deeper on YDB102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YDB102.

Explore the full profile